HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $21

Benzinga Newsdesk www.benzinga.com Negative 74.5%

Neg 74.5% Neu 0% Pos 0%

HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $27 to $21.